Barun Pradhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Barun Pradhan has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Geoffrey J. Faulkner
Mater Research Institute, University of Queensland, TRI Building, Woolloongabba, QLD 4102, Australia
41 shared publications - Juan Manuel Botto
Mater Research Institute-University of Queensland, Brisbane, QLD, Australia
41 shared publications - Liisa Kauppi
Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland
41 shared publications - Sampsa Hautaniemi
Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland
41 shared publications - Anna Vähärautio
Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland
40 shared publications - Fatih Genç
Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland
40 shared publications
Latest Publications
- 30 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6810)
X-chromosome inactivation draws L1 mutagenesis to the human X chromosome
X-chromosome inactivation (XCI) enables gene dosage compensation in XX eutherians. Long interspersed element-1 (LINE-1 or L1) retrotransposons are unusually abundant on the human X chromosome and are hypothesized to facilitate XCI. Here, we used long-read DNA sequencing to conduct a haplotype-aware analysis of engineered L1 integration preferences in the PA-1 human embryonic carcinoma cell line. Crucially, clonal XCI in PA-1 cells enabled derivation of active (Xa) and inactive (Xi) X-chromosome haplotypes. L1 integration strongly favored the Xi and other genomic regions that undergo DNA replication late in S-phase. These results suggest that the X chromosome is L1 rich because of XCI and imply that L1 integration preference for the Xi in XX individuals could potentially double the frequency of X-linked pathogenic L1 mutations in their XY descendants.
- 30 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6810)
X-chromosome inactivation draws L1 mutagenesis to the human X chromosome
X-chromosome inactivation (XCI) enables gene dosage compensation in XX eutherians. Long interspersed element-1 (LINE-1 or L1) retrotransposons are unusually abundant on the human X chromosome and are hypothesized to facilitate XCI. Here, we used long-read DNA sequencing to conduct a haplotype-aware analysis of engineered L1 integration preferences in the PA-1 human embryonic carcinoma cell line. Crucially, clonal XCI in PA-1 cells enabled derivation of active (Xa) and inactive (Xi) X-chromosome haplotypes. L1 integration strongly favored the Xi and other genomic regions that undergo DNA replication late in S-phase. These results suggest that the X chromosome is L1 rich because of XCI and imply that L1 integration preference for the Xi in XX individuals could potentially double the frequency of X-linked pathogenic L1 mutations in their XY descendants.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Identification and functional validation of inactivating mutation on a source RC-L1
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Identification and functional validation of inactivating mutation on a source RC-L1
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Catalog and Characteristics of L1 insertions identified by LDI-PCR/Nanopore-seq
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Catalog and Characteristics of L1 insertions identified by LDI-PCR/Nanopore-seq
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Association of L1 status of HGSC patients with their genomic features
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Association of L1 status of HGSC patients with their genomic features
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Primers and reaction conditions for Genotyping PCR
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Primers and reaction conditions for Genotyping PCR
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Agarose gel image showcasing results of source RC-L1s genotyping PCR
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Agarose gel image showcasing results of source RC-L1s genotyping PCR
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Within-patient variability in L1 profiles
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Within-patient variability in L1 profiles
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
PCR validation of de novo L1 insertions identified by LDI-PCR/Nanopore-seq
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
PCR validation of de novo L1 insertions identified by LDI-PCR/Nanopore-seq
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Agarose gel image showcasing results of Long-distance Inverse PCR (LDI-PCR) to detect de novo L1 retrotransposition in HGSC tumors
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Agarose gel image showcasing results of Long-distance Inverse PCR (LDI-PCR) to detect de novo L1 retrotransposition in HGSC tumors
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Association of L1 burden with clinical and lifestyle factors of HGSC patients
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer
Association of L1 burden with clinical and lifestyle factors of HGSC patients